Malignant Pleural Effusion Clinical Trial
— RIOT2Official title:
Phase I Intra-patient Dose Escalation Study of the IL-6 Receptor Antagonist Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Pleural Effusion or Peritoneal Ascites Due to Metastatic Cancer
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
Status | Recruiting |
Enrollment | 12 |
Est. completion date | January 2027 |
Est. primary completion date | January 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion Criteria: 1. Subjects age 18-89 years old with pleural effusion or peritoneal ascites due to metastatic cancer 2. Scheduled to undergo standard-of-care placement of pleural or peritoneal drainage catheter 3. ECOG performance status: 0-2 4. Able to read and sign consent form in English and provide informed consent Exclusion Criteria: 1. Laboratory abnormalities that indicate clinically significant inflammatory process AST/SGOT > 2 times the upper limit of normal ALT/SGPT > 2 times the upper limit of normal Total bilirubin > 2 times the upper limit of normal Creatinine > 2 times the upper limit of normal Hemoglobin < 8gm/dL White blood cell count < 3,000/ mm3 Platelet count < 70,000/mm3 Absolute neutrophil cell count < 2,000 per mm3 2. Subjects who are unable to comply with study procedures including travel for weekly outpatient clinic visits 3. Pregnant women 4. Active immunotherapy within 30 days; concurrent chemotherapy or targeted therapy is permitted but for patients with a history of prior immunotherapy, the most recent dose should be >30 days prior to the first treatment visit 5. Investigational drug use within 30 days prior to first treatment dose 6. History of systemic autoimmune disease 7. Patient with known hypersensitivity to tocilizumab 8. Active infection 9. Medical contraindication or history of adverse reaction to acetaminophen or diphenhydramine - |
Country | Name | City | State |
---|---|---|---|
United States | Allegheny Health Network Cancer Institute | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Successful intra-cavitary administration of tocilizumab | Number of patients with successful administration of tocilizumab | 6 weeks | |
Primary | Adverse Events | To identify the frequency and type of adverse events (AE) following intrapleural or intraperitoneal administration of tocilizumab at doses up to 2.5 mg (intrapleural) or 25 mg (intraperitoneal) using CTCAE v5.0 | 6 weeks | |
Secondary | Pharmacokinetics Analysis | Measuring serum receptor occupancy levels | 4 weeks | |
Secondary | Pharmacokinetics Analysis | Measuring intracavity fluid receptor occupancy levels | 4 weeks | |
Secondary | Biomarkers | Change in Pleural cytokine concentrations | 4 weeks | |
Secondary | Biomarkers | Change in Peritoneal Cytokine concentrations | 4 weeks | |
Secondary | Biomarkers | Change in immune cell density | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00052338 -
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Recruiting |
NCT04793607 -
Interventions for Malignant Pleural Effusions Impact on Fatigue
|
||
Recruiting |
NCT03987087 -
A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT02942043 -
Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01997190 -
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
|
Phase 1 | |
Completed |
NCT00564733 -
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04131231 -
Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion
|
N/A | |
Completed |
NCT02674243 -
Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion
|
Phase 3 | |
Terminated |
NCT01004510 -
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00528645 -
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT00313066 -
Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion
|
Phase 4 | |
Terminated |
NCT04236037 -
Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura
|
N/A | |
Completed |
NCT05372055 -
Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients
|
||
Not yet recruiting |
NCT04914598 -
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
|
Phase 3 | |
Recruiting |
NCT04322136 -
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
|
N/A | |
Recruiting |
NCT03973957 -
Talc Outpatient Pleurodesis With Indwelling Catheter
|
N/A | |
Recruiting |
NCT05923515 -
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
|
Phase 1 | |
Completed |
NCT02649894 -
Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
|
N/A | |
Recruiting |
NCT03403855 -
Rocket® Pleural Catheters: QOL, Feasibility and Satisfaction in Recurrent MPE Patients
|
N/A |